A New England-based company that specializes in enhancing athletes' grip struck a deal with two sharks on "Shark Tank." ...

Velocity One, a newly formed aerospace manufacturing holding company, announced the acquisition of Emcore Corp. for $31.4 ...

Trace Neuroscience, which launched this week with $101 million, benefited from last year’s approval of Qalsody. Its CEO spoke ...

Thome covers the Healthcare sector, focusing on stocks such as Alkermes, Jazz Pharmaceuticals ... AnaptysBio (ANAB) Company Description: AnaptysBio, Inc. is a clinical stage biotechnology company, ...

Intuitive Machines suggested the need for “reformulation” of NASA’s Artemis lunar exploration campaign to accommodate budget issues and delays.

“It's almost like the great equalizer. You put it on, rub it in, clap away all the residual dust, and then your hands, which ...

Alkermes plc announced today that management will participate at two upcoming investor conferences. Stifel Healthcare ConferenceDate/Time: Monday, Nov. 18, 2024 at 8:35 a.m. ET (1:35 p.m. GMT) ...

Stifel Nicolaus analyst Paul Matteis maintained a Buy rating on PepGen Inc. (PEPG – Research Report) on November 8 and set a price target ...

Stifel Nicolaus upgraded shares of Alkermes (NASDAQ:ALKS – Free Report) from a hold rating to a buy rating in a research note released on Tuesday, Marketbeat Ratings reports. The firm currently has ...

Stifel has upgraded Alkermes (ALKS) to buy from hold, citing increased confidence in the company’s narcolepsy drug candidate ALKS2680. Read more here.

The consensus rating for Ultragenyx Pharmaceutical is Outperform, based on 6 analyst ratings. With an average one-year price target of $102.33, there's a potential 100.69% upside.

Myrobalan Therapeutics, a biotechnology company developing novel oral small-molecule therapies to repair damage and restore brain function in high-unm ...